Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Dec 12;7(23):7382-7383.
doi: 10.1182/bloodadvances.2023011243.

Time to include IGLV3-21R110 status in CLL prognostication?

Richard Rosenquist  1   2
Affiliations
Editorial

Time to include IGLV3-21R110 status in CLL prognostication?

Richard Rosenquist. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: R.R. received honoraria from AbbVie, AstraZeneca, Janssen, Illumina, and Roche.

Figures

None
Immunogenetic analysis in CLL. Sequencing of the clonotypic IGHV gene rearrangement identifies whether patients with CLL carry IGHV gene somatic hypermutations (M-CLL) or show few or no somatic hypermutations (U-CLL). By analyzing the IGHV-D-J gene usage and the composition of the CDR3, patients with CLL with stereotyped BcR immunoglobulins can be recognized. Here, exemplified by subset number 2 (IGHV3-21/IGLV3-21), which often shows borderline mutation status and always carries the IGLV3-21R110 mutation. Finally, the IGLV3-21R110 mutation, which occurs at the border between the IGLJ and IGLC gene, can be assessed by performing a separate multiplex PCR reaction as that proposed by Syrykh et al.
See this image and copyright information in PMC

Comment on

  • IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia.
    Syrykh C, Pons-Brun B, Russiñol N, Playa-Albinyana H, Baumann T, Duran-Ferrer M, Kulis M, Carbó-Meix A, Mozas P, Alcoceba M, González M, Navarro-Bailón A, Colado E, Payer ÁR, Aymerich M, Terol MJ, Lu J, Knisbacher BA, Hahn CK, Ruiz-Gaspà S, Enjuanes A, Wu CJ, Getz G, Zenz T, López-Guillermo A, Martín-Subero JI, Colomer D, Delgado J, Campo E, Nadeu F. Syrykh C, et al. Blood Adv. 2023 Dec 12;7(23):7384-7391. doi: 10.1182/bloodadvances.2023010132. Blood Adv. 2023. PMID: 37505099 Free PMC article. No abstract available.

References

    1. Syrykh C, Pons-Brun B, Russiňol N, et al. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia. Blood Adv. 2023;7(23):7384–7391. - PubMed
    1. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848–1854. - PubMed
    1. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760. - PubMed
    1. Agathangelidis A, Chatzidimitriou A, Chatzikonstantinou T, et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL. Leukemia. 2022;36(8):1961–1968. - PMC - PubMed
    1. Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood. 2003;101(12):4952–4957. - PubMed

MeSH terms

Substances